Long non-coding RNAs regulation of therapeutic resistance

Abstract

Non-protein coding RNAs have emerged as a regulator of cell signaling and cancer progression through regulation of cell proliferation, metastatic burden, and cancer stem cell capacity. A subtype of non-protein coding RNA is long non-protein coding RNA (lncRNA). Besides their aforementioned roles in cancer cell biology, dysregulation of lncRNAs contribute to resistance to therapeutic treatments. A couple of important therapeutic classes are chemotherapy and targeted/hormone therapies. This review highlights the variety of malignancies affected by lncRNA dysregulation and the underlying mechanism causing therapeutic resistance.

Keywords

Long non-protein coding RNA / cancer / chemotherapeutic resistance / target therapeutics / hormone therapy / and microRNA sponge

References

[1] DeVita VT Jr.A history of cancer chemotherapy..Cancer Res2008;68:8643-53

[2] Shewach DS.Introduction to cancer chemotherapeutics..Chem Rev2009;109:2859-61 PMCID:PMC4110949

[3] Dasari S.Cisplatin in cancer therapy: molecular mechanisms of action..Eur J Pharmacol2014;740:364-78 PMCID:PMC4146684

[4] Keating GM.Sorafenib: a review of its use in advanced hepatocellular carcinoma..Drugs2009;69:223-40

[5] Hagner N.Cancer chemotherapy: targeting folic acid synthesis..Cancer Manag Res2010;2:293-301 PMCID:PMC3033035

[6] Caitriona H,Daniel BL.Cancer drug resistance: an evolving paradigm..Nat Rev Cancer2013;13:714

[7] Gloss BS.Realizing the significance of noncoding functionality in clinical genomics..Exp Mol Med2018;50:97 PMCID:PMC6082831

[8] Yamada A,Lin W,Boland CR.A RNA-sequencing approach for the identification of novel long non-coding RNA biomarkers in colorectal cancer..Sci Rep2018;8:575 PMCID:PMC5766599

[9] Huarte M.The emerging role of lncRNAs in cancer..Nat Med2015;21:1253-61

[10] Quinn JJ.Unique features of long non-coding RNA biogenesis and function..Nat Rev Genet2016;17:47-62

[11] Zhang Y,Chen LL.Life without A tail: new formats of long noncoding RNAs..Int J Biochem Cell Biol2014;54:338-49

[12] Ransohoff JD,Khavari PA.The functions and unique features of long intergenic non-coding RNA..Nat Rev Mol Cell Biol2018;19:143-57 PMCID:PMC5889127

[13] Li Y,Feng B.Long noncoding RNA lncARSR promotes doxorubicin resistance in hepatocellular carcinoma via modulating PTEN-PI3K/Akt pathway..J Cell Biochem2017;118:4498-507

[14] Shi SJ,Yu B,Jin Y.LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer..Oncotarget2015;6:11652-63 PMCID:PMC4484483

[15] Godinho MF,Look MP,Sleijfer S.BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib..Br J Cancer2012;107:947-55 PMCID:PMC3464772

[16] Li Y,Ning H,Zhou X.Down-regulation of CASC2 contributes to cisplatin resistance in gastric cancer by sponging miR-19a..Biomed Pharmacother2018;108:1775-82

[17] Zhang Y,Yu S,Zhang Z.Long non-coding RNA FAM84B-AS promotes resistance of gastric cancer to platinum drugs through inhibition of FAM84B expression..Biochem Biophys Res Commun2019;509:753-62

[18] Zhang CL,Ma XL.Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2..Cancer Lett2017;396:66-75

[19] An Q,Xu N.Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143..Biomed Pharmacother2018;103:415-20

[20] Li W,Wang H,Zhang J.Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer..Oncotarget2016;7:27778-86 PMCID:PMC5053687

[21] Cai Q,Jin L,Zhou D.Long non-coding RNA GBCDRlnc1 induces chemoresistance of gallbladder cancer cells by activating autophagy..Mol Cancer2019;18:82 PMCID:PMC6449938

[22] Han J,Wu X,Dong X.Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway..Toxicol Appl Pharmacol2018;359:55-61

[23] Jia L,Chen Y.The silencing of LncRNA-H19 decreases chemoresistance of human glioma cells to temozolomide by suppressing epithelial-mesenchymal transition via the Wnt/beta-Catenin pathway..Onco Targets Ther2018;11:313-21 PMCID:PMC5769571

[24] Xiao J,Jin F,Ma Y.LncRNA HANR promotes tumorigenesis and increase of chemoresistance in hepatocellular carcinoma..Cell Physiol Biochem2017;43:1926-38

[25] Chen X,Meng F,Jin X.The long noncoding RNA HIF1A-AS2 facilitates cisplatin resistance in bladder cancer..J Cell Biochem2019;120:243-52

[26] Xue X,Zhang A,Kim J.LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer..Oncogene2016;35:2746-55 PMCID:PMC4791209

[27] Xiao Z,Chen Z,Zhou K.LncRNA HOTAIR is a prognostic biomarker for the proliferation and chemoresistance of colorectal cancer via MiR-203a-3p-mediated Wnt/ss-catenin signaling pathway..Cell Physiol Biochem2018;46:1275-85

[28] Yang Y,Yang Y,Huang J.Silencing of LncRNA-HOTAIR decreases drug resistance of non-small cell lung cancer cells by inactivating autophagy via suppressing the phosphorylation of ULK1..Biochem Biophys Res Commun2018;497:1003-10

[29] Zhou H,Zhong D.Knockdown of lncRNA HOXD-AS1 suppresses proliferation, migration and invasion and enhances cisplatin sensitivity of glioma cells by sponging miR-204..Biomed Pharmacother2019;112:108633

[30] Gu P,Xie R,Xie W.lncRNA HOXD-AS1 regulates proliferation and chemo-resistance of castration-resistant prostate cancer via recruiting WDR5..Mol Ther2017;25:1959-73 PMCID:PMC5542640

[31] Chen X,Gu P,Han J.Long Noncoding RNA LBCS inhibits self-renewal and chemoresistance of bladder cancer stem cells through epigenetic silencing of SOX2..Clin Cancer Res2019;25:1389-403

[32] Zhuang J,Yang L,Lu Q.TGFbeta1 promotes gemcitabine resistance through regulating the LncRNA-LET/NF90/miR-145 signaling axis in bladder cancer..Theranostics2017;7:3053-67 PMCID:PMC5566105

[33] Ma G,Liu F.Long noncoding RNA LINC00460 promotes the gefitinib resistance of nonsmall cell lung cancer through epidermal growth factor receptor by sponging miR-769-5p..DNA Cell Biol2019;38:176-83 PMCID:PMC6383575

[34] He J,Geng H.Long non-coding RNA Linc00518 promotes paclitaxel resistance of the human prostate cancer by sequestering miR-216b-5p..Biol Cell2019;111:39-50

[35] Han Z.Long non-coding RNA LUCAT1 modulates methotrexate resistance in osteosarcoma via miR-200c/ABCB1 axis..Biochem Biophys Res Commun2018;495:947-53

[36] He W,Wang C,Zhao Y.MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer..Oncogene2019;38:4637-54

[37] Li P,Wang H,Liu T.MALAT1 is associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2..Mol Cancer Ther2017;16:739-51

[38] Li P,Xu J,Liang G.microRNA-301b-3p downregulation underlies a novel inhibitory role of long non-coding RNA MBNL1-AS1 in non-small cell lung cancer..Stem Cell Res Ther2019;10:144 PMCID:PMC6528355

[39] Liu J,Lu K,Pan X.The long noncoding RNA MEG3 contributes to cisplatin resistance of human lung adenocarcinoma..PLoS One2015;10:e0114586 PMCID:PMC4439130

[40] Chen S.Long noncoding RNA NEAT1 suppresses sorafenib sensitivity of hepatocellular carcinoma cells via regulating miR-335-c-Met..J Cell Physiol2019;

[41] Hu Y,Wang L,Sun F.Knockdown of the oncogene lncRNA NEAT1 restores the availability of miR-34c and improves the sensitivity to cisplatin in osteosarcoma..Biosci Rep2018;38: PMCID:PMC6435545

[42] Tian X,Zhao H,Zhu C.Long non-coding RNA NEAT1 contributes to docetaxel resistance of prostate cancer through inducing RET expression by sponging miR-34a..RSC Advances2017;7:42986-96

[43] Song L,Gan Y,Xu Y.Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATbeta/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p..J Cell Biochem2019;120:9656-66

[44] Fan H,Yao XQ.Knockdown of long noncoding RNA PVT1 reverses multidrug resistance in colorectal cancer cells..Mol Med Rep2018;17:8309-15 PMCID:PMC5984006

[45] Ping G,Zhang L,Zhang Y.Silencing long noncoding RNA PVT1 inhibits tumorigenesis and cisplatin resistance of colorectal cancer..Am J Transl Res2018;10:138-49 PMCID:PMC5801353

[46] Du P,Qin Y,Patel R.LncRNA PVT1 mediates antiapoptosis and 5-fluorouracil resistance via increasing Bcl2 expression in gastric cancer..J Oncol2019;2019:10 PMCID:PMC6530232

[47] Zhang Z,Lu C,Zeng A.Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma..J Exp Clin Cancer Res2019;38:166 PMCID:PMC6469146

[48] Li W,He C,Li Z.LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells..J Exp Clin Cancer Res2019;38:183 PMCID:PMC6499991

[49] Wang P,Ma H.LncRNA SNHG12 contributes to multidrug resistance through activating the MAPK/Slug pathway by sponging miR-181a in non-small cell lung cancer..Oncotarget2017;8:84086-101 PMCID:PMC5663579

[50] Wang L,Feng Q.LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis..Cancer Biol Ther2019;20:261-71 PMCID:PMC6370371

[51] Song H,Shi L,Fan R.LncRNA THOR increases the stemness of gastric cancer cells via enhancing SOX9 mRNA stability..Biomed Pharmacother2018;108:338-46

[52] Mazor G,Picard D,Caren H.The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells..Cell Death Dis2019;10:246 PMCID:PMC6416247

[53] Li C,Li Y.TUG1 mediates methotrexate resistance in colorectal cancer via miR-186/CPEB2 axis..Biochem Biophys Res Commun2017;491:552-7

[54] Yang LT,Yu PF,Wang XB.Long non-coding RNA TUG1 regulates the development of multidrug resistance in hepatocellular carcinoma via P-gp and MDR1..Int J Clin Exp Med2016;9:21388-96

[55] Fan Y,Tan M,Qin Y.Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling..Febs J2014;281:1750-8

[56] Wu C.Long non-coding RNA (lncRNA) urothelial carcinoma-associated 1 (UCA1) enhances tamoxifen resistance in breast cancer cells via inhibiting mTOR signaling pathway..Med Sci Monit2016;22:3860-7 PMCID:PMC5077288

[57] Bian Z,Zhang J,Quan C.LncRNA-UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p..Sci Rep2016;6:23892 PMCID:PMC4820696

[58] Cheng N,Ren S,Wang Q.Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer..Oncotarget2015;6:23582-93 PMCID:PMC4695138

[59] Wang X,Ma B.The UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate cancer cells..Cancer Chemother Pharmacol2016;78:1025-31

[60] Zhu J,Yang D,Yan X.Knockdown of long non-coding RNA XIST inhibited doxorubicin resistance in colorectal cancer by upregulation of miR-124 and downregulation of SGK1..Cell Physiol Biochem2018;51:113-28

[61] Xu W,Li Y,Zhang F.Silencing of lncRNA ZFAS1 inhibits malignancies by blocking Wnt/beta-catenin signaling in gastric cancer cells..Biosci Biotechnol Biochem2018;82:456-65

[62] Schirrmacher V.From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment (Review)..Int J Oncol2019;54:407-19 PMCID:PMC6317661

[63] Allen KE.Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics..Mol Cancer Ther2010;9:3126-36

[64] Ralhan R.Alkylating agents and cancer therapy..Expert Opin Ther Pat2007;17:1061-75

[65] Lee CY.Strategies of temozolomide in future glioblastoma treatment..Onco Targets Ther2017;10:265-70 PMCID:PMC5234558

[66] Chen X,Dong H,Zhang Y.Platinum-based agents for individualized cancer treatment..Curr Mol Med2013;13:1603-12

[67] Matsuda A,Tango T.Quality of life in advanced non-small cell lung cancer patients receiving palliative chemotherapy: a meta-analysis of randomized controlled trials..Exp Ther Med2012;3:134-40 PMCID:PMC3438671

[68] Morgensztern D,Gao F.Trends in stage distribution for patients with non-small cell lung cancer: a national cancer database survey..J Thorac Oncol2010;5:29-33

[69] Kamat AM,Efstathiou JA,Malmstrom PU.Bladder cancer..Lancet2016;388:2796-810

[70] Kurtova AV,Mo Q,Krasnow R.Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance..Nature2015;517:209-13 PMCID:PMC4465385

[71] Luo J,Li H,Yun H.LncRNA UCA1 promotes the invasion and EMT of bladder cancer cells by regulating the miR-143/HMGB1 pathway..Oncol Lett2017;14:5556-62 PMCID:PMC5662909

[72] Wang H,He K,Cao J.LncRNA UCA1 in anti-cancer drug resistance..Oncotarget2017;8:64638-50 PMCID:PMC5610032

[73] Sastre J,Diaz-Rubio E.Chemotherapy for gastric cancer..World J Gastroenterol2006;12:204-13 PMCID:PMC4066028

[74] Oba K,Bang YJ,Burzykowski T.Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis..Eur J Cancer2013;49:1565-77

[75] Wong N,Kapoor A,Ojo D.Upregulation of FAM84B during prostate cancer progression..Oncotarget2017;8:19218-35 PMCID:PMC5386679

[76] Alcindor T.Oxaliplatin: a review in the era of molecularly targeted therapy..Curr Oncol2011;18:18-25 PMCID:PMC3031353

[77] Houthuijzen JM,Roodhart JM.The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression..Br J Cancer2012;106:1901-6 PMCID:PMC3388567

[78] Roodhart JM,Stigter EC,Gerrits J.Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids..Cancer Cell2011;20:370-83

[79] Wang T,Lee H,Tripathi SC.JAK/STAT3-regulated fatty acid beta-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance..Cell Metab2018;27:1357 PMCID:PMC6116734

[80] Rowinsky EK.The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents..Annu Rev Med1997;48:353-74

[81] Yao H,Yan S,Song L.Triple-negative breast cancer: is there a treatment on the horizon?.Oncotarget2017;8:1913-24 PMCID:PMC5352107

[82] Ivery MT.Modeling the interaction of paclitaxel with beta-tubulin..Oncol Res2003;14:1-19

[83] Raveh E,Gilon M.The H19 Long non-coding RNA in cancer initiation, progression and metastasis - a proposed unifying theory..Mol Cancer2015;14:184 PMCID:PMC4632688

[84] Attard G,Eeles RA,Tomlins SA.Prostate cancer..Lancet2016;387:70-82

[85] Chakravarty D,Nair SS,Li R.The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer..Nat Commun2014;5:5383 PMCID:PMC4241506

[86] Naganuma T.Paraspeckle formation during the biogenesis of long non-coding RNAs..RNA Biol2013;10:456-61 PMCID:PMC3672290

[87] Thorn CF,Marsh S,McLeod H.Doxorubicin pathways: pharmacodynamics and adverse effects..Pharmacogenet Genomics2011;21:440-6 PMCID:PMC3116111

[88] Misra S,Misra NC.Carcinoma of the gallbladder..Lancet Oncol2003;4:167-76

[89] Kresl JJ,Henning GT,Donohue J.Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma..Int J Radiat Oncol Biol Phys2002;52:167-75

[90] Pei G,Ni X,Wang S.Autophagy facilitates metadherin-induced chemotherapy resistance through the AMPK/ATG5 pathway in gastric cancer..Cell Physiol Biochem2018;46:847-59

[91] Arencibia JM,Bauer AF,Biondi RM.AGC protein kinases: from structural mechanism of regulation to allosteric drug development for the treatment of human diseases..Biochim Biophys Acta2013;1834:1302-21

[92] Tanaka S.Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies..J Gastroenterol2011;46:289-96

[93] Sano H,Novitskiy SV,Zaja-Milatovic S.The Foxc2 transcription factor regulates tumor angiogenesis..Biochem Biophys Res Commun2010;392:201-6 PMCID:PMC2822046

[94] Plunkett W,Xu YZ,Grunewald R.Gemcitabine: metabolism, mechanisms of action, and self-potentiation..Semin Oncol1995;22:3-10

[95] Liu X,Liu C,Yang Q.Overexpression of ABCC3 promotes cell proliferation, drug resistance, and aerobic glycolysis and is associated with poor prognosis in urinary bladder cancer patients..Tumour Biol2016;37:8367-74

[96] Sara JD,Khodadadi R,Lobo R.5-fluorouracil and cardiotoxicity: a review..Ther Adv Med Oncol2018;

[97] Miura K,Ishida K,Naitoh T.5-fu metabolism in cancer and orally-administrable 5-fu drugs..Cancers2010;2:1717-30 PMCID:PMC3837334

[98] Carter SK.Gastric cancer: current status of treatment..J Natl Cancer Inst1977;58:567-78

[99] Wilhelm S,Lynch M,Dumas J.Discovery and development of sorafenib: a multikinase inhibitor for treating cancer..Nat Rev Drug Discov2006;5:835-44

[100] Guo S,Luo Y,Zhong T.Clinical implication of long non-coding RNA NEAT1 expression in hepatocellular carcinoma patients..Int J Clin Exp Pathol2015;8:5395-402 PMCID:PMC4503113

[101] Padma VV.An overview of targeted cancer therapy..Biomedicine (Taipei)2015;5:19 PMCID:PMC4662664

[102] Guo F,Guo H.The action mechanism of lncRNA-HOTAIR on the drug resistance of non-small cell lung cancer by regulating Wnt signaling pathway..Exp Ther Med2018;15:4885-9 PMCID:PMC5958754

[103] Giaccone G.The role of gefitinib in lung cancer treatment..Clin Cancer Res2004;10:4233s-7s

[104] Arteaga CL.Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer..Breast Cancer Res2003;5:96-100 PMCID:PMC154152

[105] Gajria D.HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies..Expert Rev Anticancer Ther2011;11:263-75 PMCID:PMC3092522

[106] Montemurro F,Clavarezza M,Jacomuzzi ME.Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy..Oncologist2006;11:318-24

[107] Niedersuss-Beke D,Kunit T,Lamche M.Neoadjuvant chemotherapy with gemcitabine plus cisplatin in patients with locally advanced bladder cancer..Oncology2017;93:36-42

[108] Nishio M,Wu YL,Solomon BJ.Crizotinib versus chemotherapy in Asian patients with ALK-positive advanced non-small cell lung cancer..Cancer Res Treat2018;50:691-700 PMCID:PMC6056984

[109] Camidge DR,Clark JW,Weiss J.Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): updated safety and efficacy findings from a phase 1 trial..J Clin Oncol2018;36:9062

[110] Rau KM,Cha TL,Hung MC.The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers..Endocr Relat Cancer2005;12:511-32

[111] Fan C,Wessels L,Nuyten DS.Concordance among gene-expression-based predictors for breast cancer..N Engl J Med2006;355:560-9

[112] Harbeck N.Breast cancer..Lancet2017;389:1134-50

[113] Tremont A,Cole JT.Endocrine therapy for early breast cancer: updated review..Ochsner J2017;17:405-11 PMCID:PMC5718454

[114] Sporn MB LS.Agents for chemoprevention and their mechanism of action.2003;Holland-Frei Cancer MedicineBC Decker

[115] Godinho MF,Look MP,Foekens JA.Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer..Br J Cancer2010;103:1284-91 PMCID:PMC2967058

[116] Liu H,Yang L,Yang Z.Knockdown of long non-coding RNA UCA1 increases the tamoxifen sensitivity of breast cancer cells through inhibition of Wnt/beta-catenin pathway..PLoS One2016;11:e0168406 PMCID:PMC5158064

[117] Feng Y,Zhang Y,Li C.Methods for the study of long noncoding RNA in cancer cell signaling..Methods Mol Biol2014;1165:115-43 PMCID:PMC4142042

[118] Arun G,Akerman M,Wilkinson JE.Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss..Genes Dev2016;30:34-51 PMCID:PMC4701977

[119] Gutschner T,Eissmann M,Kim Y.The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells..Cancer Res2013;73:1180-9 PMCID:PMC3589741

[120] Yin DD,Zhang E,Zhang ZH.Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer..Tumour Biol2015;36:4851-9

[121] Marin-Bejar O,Athie A,Gonzalez J.Pint lincRNA connects the p53 pathway with epigenetic silencing by the Polycomb repressive complex 2..Genome Biol2013;14:R104 PMCID:PMC4053822

[122] Hoelder S,Workman P.Discovery of small molecule cancer drugs: successes, challenges and opportunities..Mol Oncol2012;6:155-76 PMCID:PMC3476506